Cardiovascular Drugs and Therapy

, Volume 7, Issue 6, pp 929–934

Exercise tolerance in angina is improved by mivazerol—An alpha2-adrenoceptor agonist

Authors

  • Robert Anthony Wright
    • Cardiovascular Research UnitUniversity of Edinburgh
  • Philippe Decroly
    • UCB SA, Pharma Sector
  • Tatiana Kharkevitch
    • UCB SA, Pharma Sector
  • Michael F. Oliver
    • Cardiovascular Research UnitUniversity of Edinburgh
Angina

DOI: 10.1007/BF00877729

Cite this article as:
Wright, R.A., Decroly, P., Kharkevitch, T. et al. Cardiovasc Drug Ther (1993) 7: 929. doi:10.1007/BF00877729

Summary

In a double-blind, placebo-controlled, randomized trial of treadmill exercise tolerance in six patients with chronic stable angina, intravenous mivazerol 1 µg, 2 µg, and 3 µg/kg increased in the time to onset of angina by 39%, 48%, and 76%; the time to 1-mm ST depression by 36%, 76%, and 104%; and total exercise duration by 15%, 23%, and 30%, respectively. In a subsequent double-blind, placebo-controlled, randomized trial involving a further 12 patients, a single oral dose of mivazerol of 800 µg, 1200 µg, and 1600 µg increased the time to onset of angina by 4%, 11%, and 30%; the time to 1-mm ST depression by 33%, 43%, and 53%; and the total exercise duration by 10%, 18%, and 23%, respectively. Mivazerol is an imidazole derivative with agonist properties at the alpha2-adrenoceptor and appears to be an effective antianginal. Mivazerol may improve exercise performance by attenuating the effects of exercise-induced sympathetic nervous system activity on the ischemic myocardium.

Key Words

mivazerolalpha2 adrenoceptoranginaexercise tolerance
Download to read the full article text

Copyright information

© Kluwer Academic Publishers 1994